-
US House targets data centers as midterm backlash grows
-
WTA Finals moved to Charlotte from 2027
-
French ex-minister Dati goes on trial in Renault-Nissan corruption case
-
Almost 8,000 excess deaths in France's scorched summer: statistics
-
'Being Heumann' captures joy in fight for disability rights
-
Ex-president's lengthy war crimes sentence shocks Kosovo
-
Retired great Nadal to play in exhibition matches
-
US House faces test on sweeping Russia sanctions bill
-
IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan
-
British PM says to make 'difficult decisions' as inflation rises
-
Watts, Pitt, Cruz to light up Spain's top film festival
-
TotalEnergies pumps up controversy in France with cut-price gas
-
Sweden expels Iran embassy employee over anti-Jewish threats
-
Global fuel price demos: a round-up
-
Toogood Gold's Table Mountain Sits in the Shadow of a Nevada Gold Rush
-
Leverate Launches MCP for Traders to Connect AI Assistants With Trading Platforms
-
MEXC July–August Security Report: 38.66M USDT in Risk Funds Intercepted, Futures Insurance Fund Hits 792M USDT
-
MEXC Launches $1M "Discover Your Wall Street DNA" Campaign to Help Traders Find Their Market Fit
-
'Breathing toxin every day': Indonesians choked by haze feel helpless
-
Emporio Armani names Dario Vitale new creative director
-
Stocks edge higher ahead of US Fed rate call
-
Maresca defends VAR officials after Man City benefit from error
-
Philippines ex-leader Duterte makes first in-person ICC appearance
-
Courts jails LGBTQ activists as Turkey crackdown widens
-
2027 Formula One calendar includes Monaco sprint race
-
French court to hear Depardieu's appeal against rape trial order: sources
-
Palestinians are the real victims, Thunberg tells Ed Sheeran
-
The German state premier hoping to halt far-right surge
-
Hashim Thaci: From 'George Washington of Kosovo' to Hague convict
-
Lebanon wants Israel security deal as prelude to peace: president to AFP
-
Amnesty says Iran committed 'crimes against humanity' in crackdown on 2022 protests
-
England's Brook keen to learn from 'hero' Pietersen after stunning ton
-
EU to ban social media for under 13s, curb access until 15
-
Saudi says Houthis target Mecca, warns of 'red line'
-
Philippines ex-leader Duterte makes first appearance at ICC
-
Phillippines ex-leader Duterte makes first appearance at ICC
-
EU chief pitches 'associate member' status for Canada
-
Lebanon wants Israel security deal, Hezbollah disarmament without confrontation: president to AFP
-
English village votes to 'secede' from UK over asylum centre plan
-
BASIS.pro Expands On-Chain Infrastructure with XDC Network Partnership and Zypher DAO as Auto Earn Goes Live
-
Wildfires push endangered Sumatran elephants to brink: Indonesian NGO
-
Samson relishing battle with teen star Sooryavanshi for India spot
-
Stocks head higher as traders prepare for Fed decision
-
Pickle-flavoured tart? AI inspires Japan's convenience stores
-
English village votes to 'secede' from UK over asylum centre
-
Macau holds first closed-door national security trial
-
Hong Kong unveils plan to align economy with China's goals
-
Bank of Japan set to raise rates under pressure from inflation, US
-
Brazilian voters the latest to eye Bukele security model with envy
-
Zverev, Shelton back on court for Davis Cup qualifiers
US approves sale of anti-overdose drug Narcan without prescription
The US drug regulator announced Wednesday that Narcan, the treatment which reverses overdoses, can be distributed without prescription, a move that comes as the country battles an acute opioid addiction crisis.
The Federal Drug Administration (FDA) said that four milligram nasal spray doses of naloxone hydrochloride, the generic name for Narcan, can be sold over the counter almost anywhere, from pharmacies to supermarkets to gas stations.
The FDA said they moved to address to mounting toll from opioid use, especially the synthetic and relatively easily made fentanyl, which has in the past five years increasingly replaced heroin and prescription pain killers as the main drug used by people addicted to opioids.
In the 12 months to October 2022, the US recorded 101,750 overdose deaths, mostly from fentanyl, the FDA said in a statement.
"The agency has used its regulatory authority to facilitate greater access to naloxone by encouraging the development of and approving an over-the-counter naloxone product to address the dire public health need,” said FDA Commissioner Robert Califf.
Narcan, by far the most commonly used version of naloxone, can quickly reverse the effects of an overdose.
Narcan will "bring someone back from basically the dead," Johnny Bailey, who has recovered from an opioid addiction and who trains people to administer the drug, explained in early March in Washington.
Previously administered mainly by injection, Narcan, produced by Emergent BioSolutions, was approved in its nasal spray form as a prescription drug in 2015.
With the toll from overdoses mounting each year, the FDA accelerated its review of Narcan for over-the-counter sales early this year.
The FDA said other producers of naloxone spray can gain approval on a case-by-case basis.
"Naloxone is a critical tool in addressing opioid overdoses," said FDA drug evaluation chief Patrizia Cavazzoni.
Th.Gonzalez--AT